Please login to the form below

Not currently logged in

Loxo Oncology

This page shows the latest Loxo Oncology news and features for those working in and with pharma, biotech and healthcare.

Lilly and Foghorn sign oncology deal

Lilly and Foghorn sign oncology deal

Loxo Oncology, an R&D group within Eli Lilly &Co, is betting that highly selective BRAHMA inhibitors are the key to addressing BRG1 mutated cancers. ... difficult chemistry challenge,” said Jacob Van Naarden, Loxo CEO and president of Lilly Oncology.

Latest news

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... This is the first US product approval for Loxo Oncology and its

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Following after the first generation of mainly antibody-based immuno-oncology drugs are a host of small-molecule drugs. ... also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    485. Array BioPharma / Loxo Oncology. Multi-year licence and collaboration. Drug candidate (preclinical) discovery of small molecule drugs for oncology targets. ... 208. Talon Therapeutics / Spectrum Pharmaceuticals. Acquisition. Haemato-oncology

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation